Professor
Robert Carlisle
BSc DPhil MSc
Associate Professor
Director of MSc in Nanotechnology for Medicine and Healthcare
Associate Director of Synthetic Biology CDT
Cavitation-Mediated Immunomodulation and Its Use with Checkpoint Inhibitors.
Maardalen M,  Carlisle R,  Coussios C,  et al. (2023)
Cavitation‐mediated Transcutaneous Delivery of Protein and Nucleotide‐based Antigen for Rapid High‐level Immune Responses
Hettinga JK,  Lyons B,  Balkaran J,  Rijal P,  Dunn‐Lawless D,  Caproni L,  Gray M,  Suslick KS,  Coussios CC,  Carlisle RC,  et al. (2023)
Clinical trial protocol for PanDox: a phase I study of targeted chemotherapy delivery to non-resectable primary pancreatic tumours using thermosensitive liposomal doxorubicin (ThermoDox®) and focused ultrasound
Spiers L,  Gray M,  Lyon P,  Sivakumar S,  Bekkali N,  Scott S,  Collins L,  Carlisle R,  Wu F,  Middleton M,  Coussios C-C,  et al. (2023)
Sonosensitive cavitation nuclei-a customisable platform technology for enhanced therapeutic delivery
Lyons B,  Balkaran JPR,  Dunn-Lawless D,  Lucian V,  Keller SB,  O'Reilly CS,  Hu L,  Rubasingham J,  Nair M,  Carlisle R,  Stride E,  Gray M,  Coussios C,  et al. (2023)
Thermosensitive liposomes: a promising step toward localised chemotherapy
Chaudhry M,  Lyon P,  Coussios C,  Carlisle R,  et al. (2022)
Improved therapeutic antibody delivery to xenograft tumors using cavitation nucleated by gas-entrapping nanoparticles
Grundy M,  Bau L,  Hill C,  Paverd C,  Mannaris C,  Kwan J,  Crake C,  Coviello C,  Coussios C,  Carlisle R,  et al. (2021)
Large-volume hyperthermia for safe and cost-effective targeted drug delivery using a clinical ultrasound-guided focused ultrasound device
Lyon PC,  Mannaris C,  Gray M,  Carlisle R,  Gleeson FV,  Cranston D,  Wu F,  Coussios CC,  et al. (2021)
In situ evaluation of spatiotemporal distribution of doxorubicin from Drug-eluting Beads in a tissue mimicking phantom
Caine M,  Bian S,  Tang Y,  Garcia P,  Henman A,  Dreher M,  Daly D,  Carlisle R,  Stride E,  Willis SL,  Lewis AL,  et al. (2021)
Quantifying cell death induced by doxorubicin, hyperthermia or HIFU ablation with flow cytometry
Lyon P,  Suomi V,  Jakeman P,  Campo L,  Coussios C,  Carlisle R,  et al. (2021)
Polymer stealthing and mucin-1 retargeting for enhanced pharmacokinetics of an oncolytic vaccinia virus
Hill C,  Grundy M,  Bau L,  Wallington S,  Balkaran J,  Ramos V,  Fisher K,  Seymour L,  Coussios C-C,  Carlisle R,  et al. (2021)
Oligonucleotide-functionalized gold nanoparticles for synchronous telomerase inhibition, radiosensitization, and delivery of theranostic radionuclides
Bavelaar BM,  Song L,  Jackson MR,  Able S,  Tietz O,  Skaripa-Koukelli I,  Waghorn PA,  Gill MR,  Carlisle RC,  Tarsounas M,  Vallis KA,  et al. (2021)
Expanding the chemical functionality of DNA nanomaterials generated by rolling circle amplification
Baker YR,  Yuan L,  Chen J,  Belle R,  Carlisle R,  El-Sagheer AH,  Brown T,  et al. (2021)
3-Bromopyruvate-mediated MCT1-dependent metabolic perturbation sensitizes triple negative breast cancer cells to ionizing radiation
Skaripa-Koukelli I,  Hauton D,  Walsby-Tickle J,  Thomas E,  Owen J,  Lakshminarayanan A,  Able S,  McCullagh J,  Carlisle R,  Vallis K,  et al. (2021)
Methods for Modification of Therapeutic Viruses.
Hill CAP,  Bau L,  Carlisle R,  et al. (2020)
Megavoltage radiosensitization of gold nanoparticles on a Glioblastoma Cancer Cell Line using a clinical platform
Kazmi F,  Vallis K,  Vellayappan BA,  Bandla A,  Yukun D,  Carlisle R,  et al. (2020)
A liposome-based cancer vaccine for a rapid and high-titre anti-ErbB-2 antibody response
Wallis J,  Katti P,  Martin AM,  Hills T,  Seymour LW,  Shenton DP,  Carlisle RC,  et al. (2020)
Expanding the Chemical Repertoire of DNA Nanomaterials Generated by Rolling Circle Amplification
Baker Y,  Yuan L,  Chen J,  Belle R,  Carlisle R,  El-Sagheer A,  Brown T,  et al. (2020)
Data for Owen et al 2020 Journal controlled release
Carlisle RC,  et al. (2020)
Focused ultrasound hyperthermia for targeted drug release from thermosensitive liposomes: results from a phase I trial
Gray MD,  Lyon P,  Mannaris C,  Folkes L,  Stratford M,  Campo L,  Chung DYF,  Scott S,  Anderson M,  Goldin R,  Carlisle R,  Wu F,  Middleton M,  Gleeson F,  Coussios C,  et al. (2019)
Focused Ultrasound Hyperthermia for Targeted Drug Release from Thermosensitive Liposomes: Results from a Phase I Trial.
Lyon PC,  Mannaris C,  Folkes LK,  Stratford M,  Campo L,  Chung DYF,  Scott S,  Anderson M,  Goldin R,  Carlisle R,  Wu F,  Middleton MARK,  Gleeson FV,  Coussios CC,  et al. (2019)
Microbubbles, nanodroplets and gas-stabilizing solid particles for ultrasound-mediated extravasation of unencapsulated drugs: an exposure parameter optimization study.
Mannaris C,  Bau L,  Grundy M,  Gray M,  Lea-Banks H,  Seth A,  Teo B,  Carlisle R,  Stride E,  Coussios C,  et al. (2019)
Novel approaches for the design, delivery and administration of vaccine technologies
Wallis J,  Shenton DP,  Carlisle R,  et al. (2019)
Ultrasound-mediated cavitation enhances the delivery of an EGFR-targeting liposomal formulation designed for chemo-radionuclide therapy
Thomas E,  Menon JU,  Owen J,  Skaripa-Koukelli I,  Wallington S,  Gray M,  Mannaris C,  Kersemans V,  Allen D,  Kinchesh P,  Smart S,  Carlisle R,  Vallis K,  et al. (2019)
Achieving systemic delivery of oncolytic viruses
Hill C,  Carlisle R,  et al. (2019)
Megavoltage Radiosensitization of Gold Nanoparticles on Glioblastoma Cancer Cell Line Using a Clinical Platform
Kazmi F,  Vallis KATHERINE,  Vellayappan B,  Bandla A,  Yukun D,  Carlisle R,  et al. (2019)
Ultrasound-Induced Mircobubble Cavitation For Optimisation Of Tumour Uptake Of Liposome-Based Chemo-Radionuclide Therapy
Vallis KA,  Thomas E,  Menon J,  Owen J,  Wallington S,  Gray M,  Skaripa-Koukelli I,  Carlisle R,  et al. (2019)
Indium-111 labelling of liposomal HEGF for radionuclide delivery via ultrasound-induced cavitation
Owen J,  Thomas E,  Menon J,  Gray M,  Skaripa-Koukelli I,  Gill ,  Wallington S,  Miller RL,  Vallis K,  Carlisle R,  et al. (2019)
Ultrasound-mediated cavitation does not decrease the activity of small molecule, antibody or viral-based medicines
Myers R,  Grundy M,  Rowe C,  Coviello CM,  Bau L,  Erbs P,  Foloppe J,  Balloul J-M,  Story C,  Coussios C,  Carlisle R,  et al. (2018)
111In-labelled polymeric nanoparticles incorporating a ruthenium-based radiosensitizer for EGFR-targeted combination therapy in oesophageal cancer cells
Gill MR,  Menon JU,  Jarman PJ,  Owen J,  Skaripa-Koukelli I,  Able S,  Thomas JA,  Carlisle R,  Vallis K,  et al. (2018)
Safety and feasibility of ultrasound-triggered targeted drug delivery of doxorubicin from thermosensitive liposomes in liver tumours (TARDOX): a single-centre, open-label, phase 1 trial
Lyon P,  Gray ,  Mannaris C,  Folkes L,  Stratford M,  Campo L,  Chung DYF,  Scott S,  Anderson M,  Goldin R,  Carlisle R,  Wu F,  Middleton M,  Gleeson F,  Coussios C,  et al. (2018)
Long-term radiological and histological outcomes following selective internal radiation therapy to liver metastases from breast cancer
Lyon P,  Winter H,  Herbschleb K,  Campo L,  Carlisle R,  Wu F,  Goldin R,  Coussios C,  Middleton M,  Gleeson F,  Boardman P,  Sharma R,  et al. (2018)
A multimodal instrument for real-time in situ study of ultrasound and cavitation mediated drug delivery
Bian S,  Seth A,  Daly D,  Carlisle R,  Stride E,  et al. (2017)
Alternative vaccine administration by powder injection: Needle-free dermal delivery of the glycoconjugate meningococcal group Y vaccine
Weissmueller NT,  Marsay L,  Schiffter HA,  Carlisle RC,  Rollier CS,  Prud'homme RK,  Pollard A,  et al. (2017)
Ultrasound-mediated cavitation-enhanced extravasation of mesoporous silica nanoparticles for controlled-release drug delivery
Paris JL,  Mannaris C,  Victoria Cabanas M,  Carlisle R,  Manzano M,  Vallet-Regi M,  Coussios C,  et al. (2017)
Radiotherapeutic Nanoparticles Containing a Ruthenium-Based Radiosensitizer for EGFR-Positive Oesophageal Cancer
Gill MR,  Menon JU,  Carlisle RC,  Thomas JA,  Jarman PJ,  Vallis KA,  et al. (2017)
SIOS scans
Carlisle R,  et al. (2017)
Polymeric cups for cavitation mediated delivery of oncolytic vaccinia virus
Myers R,  Coviello C,  Erbs P,  Foloppe J,  Rowe C,  Kwan J,  Crake C,  Finn S,  Jackson E,  Balloul J-M,  Story C,  Coussios C,  Carlisle R,  et al. (2016)
Enhancement and passive acoustic mapping of cavitation from fluorescently tagged magnetic resonance-visible magnetic microbubbles in vivo.
Crake C,  Owen J,  Smart S,  Coviello C,  Coussios C-C,  Carlisle R,  Stride E,  et al. (2016)
Cavitation-mediated extravasation and transtumoral drug delivery by microstreaming: What role do the gas nuclei and the physical properties of the therapeutic play?
Coussios C,  Myers R,  Kwan J,  Lea-Banks H,  Mo S,  Grundy M,  Mannaris C,  Duffy M,  Paverd C,  Carugo D,  Coviello C,  Stride E,  Carlisle R,  et al. (2016)
Quantification of ultrasonic texture intra-heterogeneity via volumetric stochastic modeling for tissue characterization.
Al-Kadi OS,  Chung DYF,  Carlisle RC,  Coussios CC,  Noble JA,  et al. (2015)
Quantification of ultrasonic texture intra-heterogeneity via volumetric stochastic modeling for tissue characterization
Al-Kadi OS,  Chung DYF,  Carlisle RC,  Coussios CC,  Noble JA,  et al. (2015)
Needle-free dermal delivery of a diphtheria toxin CRM197 mutant on potassium-doped hydroxyapatite microparticles
Weissmueller NT,  Schiffter HA,  Carlisle RC,  Rollier CS,  Pollard A,  et al. (2015)
Increasing the density of nanomedicines improves their ultrasound-mediated delivery to tumours
Mo S,  Carlisle R,  Laga R,  Myers R,  Graham S,  Cawood R,  Ulbrich K,  Seymour L,  Coussios C,  et al. (2015)
Ultrasound-propelled nanocups for drug delivery
Kwan J,  Myers R,  Coussios C,  al. E,  et al. (2015)
Ultrasound-induced inertial cavitation from gas-stabilizing nanoparticles.
Kwan JJ,  Graham S,  Myers R,  Carlisle R,  Stride E,  Coussios CC,  et al. (2015)
Ultrasound-induced inertial cavitation from gas-stabilizing nanoparticles.
Kwan JJ,  Graham S,  Myers R,  Carlisle R,  Stride E,  Coussios CC,  et al. (2015)
Inertial cavitation to non-invasively trigger and monitor intratumoral release of drug from intravenously delivered liposomes.
Graham SM,  Carlisle R,  Choi JJ,  Stevenson M,  Shah AR,  Myers RS,  Fisher K,  Peregrino M-B,  Seymour L,  Coussios CC,  et al. (2014)
Non-invasive and real-time passive acoustic mapping of ultrasound-mediated drug delivery.
Choi JJ,  Carlisle RC,  Coviello C,  Seymour L,  Coussios C-C,  et al. (2014)
Improving Delivery of Oncolytic Viruses to Solid Tumours
Carlisle R,  Mo S,  Myers R,  Graham S,  Laga R,  Ulbrich K,  Coussios C,  Seymour L,  et al. (2014)
Targeting of liposomes via PSGL1 for enhanced tumor accumulation.
Carlisle R,  Seymour LW,  Coussios CC,  et al. (2013)
Cavitation-enhanced delivery of a replicating oncolytic adenovirus to tumors using focused ultrasound.
Bazan-Peregrino M,  Rifai B,  Carlisle RC,  Choi J,  Arvanitis CD,  Seymour LW,  Coussios CC,  et al. (2013)
Coating of adenovirus type 5 with cleavable PEGylated gold nanoparticles for enhanced protection and circulation
Mo S,  Carlisle R,  Coussios C-C,  Seymour L,  et al. (2013)
Combining virotherapy and angiotherapy for the treatment of breast cancer.
Bazan-Peregrino M,  Sainson RCA,  Carlisle RC,  Thoma C,  Waters RA,  Arvanitis C,  Harris AL,  Hernandez-Alcoceba R,  Seymour LW,  et al. (2013)
Combining virotherapy and angiotherapy for the treatment of breast cancer
Bazan-Peregrino M,  Sainson RCA,  Carlisle RC,  Thoma C,  Waters RA,  Arvanitis C,  Harris AL,  Hernandez-Alcoceba R,  Seymour LW,  et al. (2013)
Mechanical approaches to oncological drug delivery.
Carlisle R,  Coussios C-C,  et al. (2013)
Enhanced tumor uptake and penetration of virotherapy using polymer stealthing and focused ultrasound.
Carlisle R,  Choi J,  Bazan-Peregrino M,  Laga R,  Subr V,  Kostka L,  Ulbrich K,  Coussios C,  Seymour LW,  et al. (2013)
Use of micro- and nano-sized inertial cavitation nuclei to trigger and map drug release from cavitation-sensitive liposomes.
Graham SM,  Myers RS,  Choi J,  Bazan-Peregrino M,  Seymour L,  Carlisle R,  Coussios CC,  et al. (2013)
Development of a Positive-readout Mouse Model of siRNA Pharmacodynamics.
Stevenson M,  Carlisle R,  Davies B,  Preece C,  Hammett M,  Liu W-L,  Fisher KD,  Ryan A,  Scrable H,  Seymour LW,  et al. (2013)
Goldnanoparticles for the enhancement ofadenovirus stealthing
Mo S,  Myers R,  Carlisle R,  Coussios C,  Seymour L,  et al. (2013)
Increased Adenovirus density for increased ultrasound-mediated delivery to tumors
Carlisle RC,  Mo S,  Myers R,  Graham S,  Mylonopoulou E,  Cawood R,  Seymour LW,  Coussios CC,  et al. (2013)
Polymer coatings for delivery of nucleic acid therapeutics.
Laga R,  Carlisle R,  Tangney M,  Ulbrich K,  Seymour LW,  et al. (2012)
Polymer coatings for delivery of nucleic acid therapeutics
Laga R,  Carlisle R,  Tangney M,  Ulbrich K,  Seymour LW,  et al. (2012)
Ultrasound-enhanced drug delivery for cancer.
Mo S,  Coussios C-C,  Seymour L,  Carlisle R,  et al. (2012)
Targeting of liposomes via PSGL1 for enhanced tumor accumulation
Carlisle R,  Seymour LW,  Coussios CC,  et al. (2012)
Polymer-modified gene delivery vectors retargeted with recombinant proteins
Pola R,  Pechar M,  Ulbrich K,  Carlisle RC,  Willemsen RA,  Seymour LW,  et al. (2012)
Active adenoviral vascular penetration by targeted formation of heterocellular endothelial-epithelial syncytia.
Chen HH,  Cawood R,  El-Sherbini Y,  Purdie L,  Bazan-Peregrino M,  Seymour LW,  Carlisle RC,  et al. (2011)
Inhibition of Immune-suppressive TGF beta in Tumour Models
Alamoudi A,  Carlisle R,  Cawood R,  Fisher K,  Seymour L,  et al. (2011)
Pre-immune Models for Improved Vaccine Design
Illingworth S,  Di Y,  Carlisle R,  Seymour L,  Fisher K,  et al. (2011)
Optimally stealthed Adenovirus serotype 5 shows enhanced activity and resistance to neutralisation
Thoma C,  Subr V,  Illingworth S,  Morrison J,  Fisher K,  Ulbrich K,  Seymour LW,  Carlisle R,  et al. (2011)
Ultrasound-enhanced delivery of polymer-coated oncolytic adenovirus for tumour growth inhibition
Carlisle R,  Choi J,  Kostka L,  Bazan-Peregrino M,  Ulbrich K,  Coussios C,  Seymour L,  et al. (2011)
Multi-component polymeric system for tumour cell-specific gene delivery using a universal bungarotoxin linker.
Willemsen RA,  Pechar M,  Carlisle RC,  Schooten E,  Pola R,  Thompson AJ,  Seymour LW,  Ulbrich K,  et al. (2010)
Multi-component Polymeric System for Tumour Cell-Specific Gene Delivery Using a Universal Bungarotoxin Linker
Willemsen RA,  Pechar M,  Carlisle RC,  Schooten E,  Pola R,  Thompson AJ,  Seymour LW,  Ulbrich K,  et al. (2010)
Human Prostate Stem Cells Support Replication of a Prostate-Targeted, Conditionally Replicating Adenovirus
Frazier A,  Carlisle R,  Evans H,  Georgopoulos L,  Thomson A,  Fisher K,  Seymour L,  Maitland N,  et al. (2010)
Active adenoviral vascular penetration by targeted formation of heterocellular endothelial-epithelial syncytia.
Chen HH,  Cawood R,  El-Sherbini Y,  Purdie L,  Bazan-Peregrino M,  Seymour LW,  Carlisle RC,  et al. (2010)
Adenovirus-derived vectors for prostate cancer gene therapy.
de Vrij J,  Willemsen RA,  Lindholm L,  Hoeben RC,  GIANT Consortium ,  Bangma CH,  Barber C,  Behr J-P,  Briggs S,  Carlisle R,  Cheng W-S,  Dautzenberg IJC,  de Ridder C,  Dzojic H,  Erbacher P,  Essand M,  Fisher K,  Frazier A,  Georgopoulos LJ,  Jennings I,  Kochanek S,  Koppers-Lalic D,  Kraaij R,  Kreppel F,  Magnusson M,  Maitland N,  Neuberg P,  Nugent R,  Ogris M,  Remy J-S,  Scaife M,  Schenk-Braat E,  Schooten E,  Seymour L,  Slade M,  Szyjanowicz P,  Totterman T,  Uil TG,  Ulbrich K,  van der Weel L,  van Weerden W,  Wagner E,  Zuber G,  et al. (2010)
Clinical adenoviral gene therapy for prostate cancer.
Schenk E,  Essand M,  Bangma CH,  GIANT FP6 Consortium ,  Barber C,  Behr J-P,  Briggs S,  Carlisle R,  Cheng W-S,  Danielsson A,  Dautzenberg IJC,  Dzojic H,  Erbacher P,  Fisher K,  Frazier A,  Georgopoulos LJ,  Hoeben R,  Kochanek S,  Koppers-Lalic D,  Kraaij R,  Kreppel F,  Lindholm L,  Magnusson M,  Maitland N,  Neuberg P,  Nilsson B,  Ogris M,  Remy J-S,  Scaife M,  Schooten E,  Seymour L,  Totterman T,  Uil TG,  Ulbrich K,  Veldhoven-Zweistra JLM,  de Vrij J,  van Weerden W,  Wagner E,  Willemsen R,  et al. (2010)
Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virus-adenovirus receptor and complement receptor 1.
Carlisle RC,  Di Y,  Cerny AM,  Sonnen AF-P,  Sim RB,  Green NK,  Subr V,  Ulbrich K,  Gilbert RJC,  Fisher KD,  Finberg RW,  Seymour LW,  et al. (2009)
Human prostate stem cells support replication of a prostate-targeted, conditionally replicating adenovirus
Frazier A,  Carlisle R,  Evans H,  Georgopoulos L,  Thomson A,  Fisher K,  Seymour L,  Maitland N,  et al. (2009)
Coating of adenovirus type 5 with polymers containing quaternary amines prevents binding to blood components.
Subr V,  Kostka L,  Selby-Milic T,  Fisher K,  Ulbrich K,  Seymour LW,  Carlisle RC,  et al. (2009)
Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virus-adenovirus receptor and complement receptor 1
Carlisle RC,  Di Y,  Cerny AM,  Sonnen AF-P,  Sim RB,  Green NK,  Subr V,  Ulbrich K,  Gilbert RJC,  Fisher KD,  Finberg RW,  Seymour LW,  et al. (2009)
Retargeting adenovirus infection to endothelial cells in vitro via FLK-1 and E-selectin
Bachtarzi H,  Stevenson M,  Carlisle R,  Briggs S,  Phipps S,  Fisher K,  Seymour L,  et al. (2008)
Factors influencing retention of adenovirus within tumours following direct intratumoural injection.
Bazan-Peregrino M,  Carlisle RC,  Purdie L,  Seymour LW,  et al. (2008)
Coating of adeno-associated virus with reactive polymers can ablate virus tropism, enable retargeting and provide resistance to neutralising antisera.
Carlisle RC,  Benjamin R,  Briggs SS,  Sumner-Jones S,  McIntosh J,  Gill D,  Hyde S,  Nathwani A,  Subr V,  Ulbrich K,  Seymour LW,  Fisher KD,  et al. (2008)
Comparison of molecular strategies for breast cancer virotherapy using oncolytic adenovirus.
Bazan-Peregrino M,  Carlisle RC,  Hernandez-Alcoceba R,  Iggo R,  Homicsko K,  Fisher KD,  Halldén G,  Mautner V,  Shen Y,  Seymour LW,  et al. (2008)
Development of hydrophilic polymers to reduce the interaction of adenovirus type 5 with human blood components
Carlisle R,  Subr V,  Pola R,  Ulbrich K,  Seymour LW,  et al. (2008)
Virotherapy expressing regulatory angiogenic gene therapy in treatment of breast cancer
Bazan-Peregrino M,  Sainson R,  Carlisle R,  Waters R,  Harris AL,  Hernandez-Alcoceba R,  Seymour LW,  et al. (2008)
Use of synthetic vectors for neutralising antibody resistant delivery of replicating adenovirus DNA.
Carlisle RC,  Briggs SS,  Hale AB,  Green NK,  Fisher KD,  Etrych T,  Ulbrich K,  Mautner V,  Seymour LW,  et al. (2006)
Ultrasound-enhanced transfection activity of HPMA-stabilized DNA polyplexes with prolonged plasma circulation.
Zhou Q-H,  Miller DL,  Carlisle RC,  Seymour LW,  Oupicky D,  et al. (2005)
Polymer-coated polyethylenimine/DNA complexes designed for triggered activation by intracellular reduction.
Carlisle RC,  Etrych T,  Briggs SS,  Preece JA,  Ulbrich K,  Seymour LW,  et al. (2004)
Polymer-coated polyplexes designed for triggered activation utilising intracellular reduction
Briggs SS,  Carlisle RC,  Etrych T,  Ulbrich K,  Preece JA,  Seymour LW,  et al. (2004)
Use of adenovirus proteins to enhance the transfection activity of synthetic gene delivery systems.
Carlisle RC,  et al. (2002)
Peptide-mediated RNA delivery: a novel approach for enhanced transfection of primary and post-mitotic cells.
Bettinger T,  Carlisle R,  Read ML,  Ogris M,  Seymour L,  et al. (2001)
Adenovirus hexon protein enhances nuclear delivery and increases transgene expression of polyethylenimine/plasmid DNA vectors
Carlisle R,  Bettinger T,  Ogris M,  Hale S,  Mautner V,  Seymour L,  et al. (2001)
Targeting of Drugs
Carlisle RC,  et al. (2000)
Systems for gene delivery based on combination of viral and non-viral vectors
Carlisle RC,  Fisher KD,  Parker AL,  Seymour LW,  et al. (2000)